Management of Chronic Neutropenia with Lymphocytosis

Diagnostic Workup Required

The American College of Physicians recommends obtaining a peripheral blood smear immediately to assess for large granular lymphocytes, dysplastic changes, or abnormal cell morphology, as these findings distinguish between benign chronic neutropenia and lymphoproliferative disorders 1
The National Comprehensive Cancer Network suggests performing flow cytometry on peripheral blood to identify monoclonal B-cell or T-cell populations, as chronic lymphocytic leukemia (CLL) or LGL leukemia commonly present with this pattern 2
Checking immunoglobulin levels is recommended, as paraproteinemia or hypogammaglobulinemia may accompany lymphoproliferative disorders and predispose to recurrent infections independent of neutropenia 2

For patients with severe neutropenia (ANC <0.5 × 10⁹/L), the National Comprehensive Cancer Network recommends initiating G-CSF (filgrastim) at low doses of 1-3 mcg/kg/day subcutaneously on an intermittent basis, with a strength of evidence of high 3, 4, 1
The American Society of Clinical Oncology advises against using pegfilgrastim in chronic neutropenia because its long-acting nature prevents the dose adjustments necessary for chronic management 1
For patients with moderate neutropenia (ANC 0.5-1.0 × 10⁹/L), the National Comprehensive Cancer Network suggests considering G-CSF therapy only if the patient experiences recurrent severe infections, with a strength of evidence of moderate 3, 4

The European Society for Medical Oncology recommends monitoring complete blood counts twice weekly during initial G-CSF therapy, and once stable, frequency can be reduced but regular monitoring remains essential to adjust dosing and maintain ANC in the target range, with a strength of evidence of high 3, 4
The National Comprehensive Cancer Network notes that the greatest concern with severe congenital neutropenia (Kostmann syndrome) is evolution to myelodysplasia and acute leukemia, occurring in approximately 7% of patients, with higher risk in those requiring higher G-CSF doses, with a strength of evidence of high 3, 4

The American College of Physicians advises against attributing all future infections solely to mild neutropenia, as patients with lymphoproliferative disorders may have functional hypogammaglobulinemia leading to recurrent encapsulated bacterial infections unrelated to neutrophil counts, with a strength of evidence of moderate 2
The European Society for Medical Oncology recommends avoiding initiating G-CSF in patients with ANC >1.0 × 10⁹/L without documented recurrent severe infections, as this represents unnecessary expense and potential toxicity without proven benefit, with a strength of evidence of high 6, 2